Literature DB >> 31858519

Cardiomyocyte-Specific JunD Overexpression Increases Infarct Size following Ischemia/Reperfusion Cardiac Injury by Downregulating Sirt3.

Alexander Akhmedov1,2,3, Fabrizio Montecucco4,5, Sarah Costantino1,2,3, Daria Vdovenko1,2,3, Ariane Schaub Clerigué1,2,3, Daniel S Gaul1,2,3, Fabienne Burger6, Aline Roth6, Federico Carbone4, Luca Liberale1,2,3, Mohammad Amrollahi-Sharifabadi1,2, Valerio Gaetano Vellone7,8, Urs Eriksson1,2,9, Christian M Matter1,2,3, Lindsey A Crowe10, Jean-Paul Vallée10, Francesco Paneni1,2,3, Paul M Vanhoutte11, Giovanni G Camici1,2,3, François Mach6, Thomas F Lüscher1,2,12.   

Abstract

Ischemia/reperfusion (I/R) injury in acute myocardial infarction activates several deleterious molecular mechanisms. The transcription factor JunD regulates pathways involved in oxidative stress as well as in cellular proliferation, differentiation, and death. The present study investigated the potential role of JunD as a modulator of myocardial injury pathways in a mouse model of cardiac I/R injury. Infarct size, systemic and local inflammation, and production of reactive oxygen species, as well as cytosolic and mitochondrial apoptotic pathways were investigated in adult males after myocardial I/R. In wild-type (WT) mice, 30 minutes after ischemia and up to 24 hours following reperfusion, cardiac JunD messenger ribonucleic acid expression was reduced while JunB increased. Cardiac-specific JunD overexpressing mice (JunDTg/0 ) displayed larger infarcts compared with WT. However, postischemic inflammatory or oxidative responses did not differ. JunD overexpression reduced Sirt3 transcription by binding to its promoter, thus leading to mitochondrial dysfunction, myocardial cell death, and increased infarct size. On the other hand, JunD silencing reduced, while Sirt3 silencing increased infarct size. In human myocardial autopsy specimens, JunD-positive areas within the infarcted left ventricle staining corresponded to undetectable Sirt3 areas in consecutive sections of the same heart. Cardiac-specific JunD overexpression increases myocardial infarct size following I/R. These effects are mediated via Sirt3 transcriptional repression, mitochondrial swelling, and increased apoptosis, suggesting that JunD is a key regulator of myocardial I/R injury. The present data set the stage for further investigation of the potential role of Sirt3 activation as a novel target for the treatment of acute myocardial infarction. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31858519     DOI: 10.1055/s-0039-3400299

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  5 in total

1.  SirT3 activates AMPK-related mitochondrial biogenesis and ameliorates sepsis-induced myocardial injury.

Authors:  Ting Xin; Chengzhi Lu
Journal:  Aging (Albany NY)       Date:  2020-07-28       Impact factor: 5.682

2.  Dexmedetomidine Ameliorates Hippocampus Injury and Cognitive Dysfunction Induced by Hepatic Ischemia/Reperfusion by Activating SIRT3-Mediated Mitophagy and Inhibiting Activation of the NLRP3 Inflammasome in Young Rats.

Authors:  Wenli Yu; Jingshu Lyu; Lili Jia; Mingwei Sheng; Hongli Yu; Hongyin Du
Journal:  Oxid Med Cell Longev       Date:  2020-11-20       Impact factor: 6.543

3.  Dexmedetomidine alleviates hepatic ischaemia-reperfusion injury via the PI3K/AKT/Nrf2-NLRP3 pathway.

Authors:  Yan Wu; Gaolin Qiu; Hainie Zhang; Leilei Zhu; Gao Cheng; Yiqiao Wang; Yuanhai Li; Weiwei Wu
Journal:  J Cell Mol Med       Date:  2021-10-19       Impact factor: 5.310

4.  The histone demthylase KDM3A protects the myocardium from ischemia/reperfusion injury via promotion of ETS1 expression.

Authors:  Xin Guo; Bo-Fang Zhang; Jing Zhang; Gen Liu; Qi Hu; Jing Chen
Journal:  Commun Biol       Date:  2022-03-25

5.  JunD Regulates Pancreatic β-Cells Function by Altering Lipid Accumulation.

Authors:  Kexin Wang; Yixin Cui; Peng Lin; Zhina Yao; Yu Sun
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-16       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.